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ABSTRACT: A novel ciprofloxacin−siderophore Trojan Horse antimicrobial was
prepared by incorporating key design features of salmochelin, a stealth siderophore
that evades mammalian siderocalin capture via its glycosylated catechol units.
Assessment of the antimicrobial activity of the conjugate revealed that attachment of
the salmochelin mimic resulted in decreased potency, compared to ciprofloxacin,
against two Escherichia coli strains, K12 and Nissle 1917, in both iron replete and
deplete conditions. This observation could be attributed to a combination of
reduced DNA gyrase inhibition, as confirmed by in vitro DNA gyrase assays, and
reduced bacterial uptake. Uptake was monitored using radiolabeling with iron-
mimetic 67Ga3+, which revealed limited cellular uptake in E. coli K12. In contrast,
previously reported staphyloferrin-based conjugates displayed a measurable uptake
in analogous 67Ga3+ labeling studies. These results suggest that, in the design of
Trojan Horse antimicrobials, the choice of siderophore and the nature and length of
the linker remain a significant challenge.
KEYWORDS: siderophores, antibiotics, drug design, radiolabeling, bioinorganic chemistry
T he problem of antimicrobial resistance has reached acritical level, and authorities now believe humankind is
entering a post-antibiotic era where minor infections and
routine medical procedures will become major morbidity
threats.1−4 New strategies in the form of new antibiotic targets
or modification of current antibiotics to bypass resistance
mechanisms are urgently needed.4−8 One approach is a Trojan
Horse delivery strategy that targets outer membrane barrier
permeability resistance9−13 by utilizing bacterial iron transport,
mediated by siderophores, to promote active antibiotic uptake;
a number of examples can be found in the literature.14−20 This
strategy has been met with some success, with a number of
siderophore−drug conjugates entering clinical trials.4,21−23
One example, cefiderocol (Fetroja, Figure 1), was recently
approved by the U.S. Food and Drug Administration (FDA)
for treatment of complicated urinary tract infections
(cUTIs).24
Salmochelin siderophores, identified in 2003,25 are a family
of siderophores consisting of glycosylated variants of the high-
Fe3+-affinity tris-catecholate siderophore enterobactin pro-
duced by many of the Enterobacteriaceae.26 The family derives
from the diglycosylated hexadentate salmochelin S4 (Figure 2)
and includes a series of di- and monoglycosylated hydrolysis
products.27 Salmochelins are biosynthesized by a range of
bacteria, including Salmonella spp. and various pathogenic
E. coli strains.25,28,29
The salmochelins belong to a class of stealth siderophores,
which maintain their role in bacterial iron acquisition while
evading the host innate immune response.30 As a response to
an invading pathogen, the mammalian host secretes
immunoprotein siderocalin to capture Fe3+-loaded catecho-
late-based siderophores.31,32 The glycosyl units in the
salmochelins prevent siderocalin binding, thus allowing the
siderophores to avoid capture. The ability to produce and
utilize salmochelins relies on the iroA gene cluster,30 which
encodes the enzymes responsible for the glycosylation of
catechol units, the secretion of the biosynthesized salmoche-
lins, the uptake of their Fe3+ complexes, and finally, the
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Figure 1. Structure of FDA-approved Trojan Horse antibiotic
cefiderocol (antibiotic unit highlighted in red).
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hydrolysis of both the apo- and Fe3+-bound siderophores.33
While the salmochelin uptake mechanism34,35 is thought to
share similarities with that of enterobactin,18,36−38 the
enterobactin receptor protein FepA, found in all E. coli, is
unable to mediate significant uptake of salmochelin S4,
whereas the outer membrane receptor protein IroN, which is
expressed only in strains that harbor iroA, allows uptake of
both salmochelin S4 and enterobactin (see Figure 3).25 This
key difference means that the presence of the iroA gene cluster
is considered a virulence factor.
The production of siderocalin by the host may limit the
application of catecholate siderophores in Trojan Horse
antimicrobials, unless the siderophore component is structur-
ally modified to evade the immune response, while maintaining
high affinity for Fe3+. The use of salmochelin-based side-
rophore components offers the opportunity of specifically
targeting bacteria that express the salmochelin transport
machinery, while minimizing disruptions to the host micro-
biome. This approach has been successfully demonstrated by
Nolan et al. with the chemoenzymatic synthesis of glucosylated
enterobactin−β-lactam conjugates (Figure 4).39
As part of our wider investigation into fluoroquinolone
siderophore conjugates,40−42 we herein report the design and
synthesis of a first generation ciprofloxacin−salmochelin S4
inspired Trojan Horse antimicrobial 1 (Figure 5), designed to
evade the mammalian siderocalin immune response and to
selectively target bacteria expressing salmochelin transport
machinery.
■ RESULTS AND DISCUSSION
Design and Synthesis. In our approach to the design of a
first generation salmochelin S4-inspired ciprofloxacin con-
jugate, the salmochelin S4 structure was simplified to a
synthetically accessible structure, comprising an aliphatic link
based on L-lysine between the catechol units and a reduction of
siderophore denticity from hexadentate to tetradentate. L-
Lysine was utilized to mimic the chirality and exact length of
the backbone between the catechol moieties in salmochelin S4
Figure 2. Chemical structures of siderophores: enterobactin, linear
enterobactin dimer, and salmochelin S4, with characteristic
glycosylated catechol units of salmochelin S4 highlighted.
Figure 3. Simplified schematic representation of the outer membrane
receptor proteins involved in Fe3+-siderophore uptake in all E. coli
(left) and pathogenic E. coli capable of producing salmochelin (right).
Figure 4. Salmochelin−β lactam conjugate designed and synthesized
by Nolan and co-workers (antibiotic component in red, chemical
linker in blue, and siderophore in black).
Figure 5. Salmochelin S4-inspired Trojan Horse antimicrobial.
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in a hydrolytically stable manner; the ester backbone in
salmochelin is prone to hydrolysis under physiological
conditions. The tetradentate siderophore mimic allows for
improved synthetic tractability compared to when the full
triserine scaffold of salmochelin S4 is used. The carboxylic acid
group of the lysine moiety provides an attachment point for
the antimicrobial. It was shown previously that tetradentate,
diamine-linked bis(catecholates) can function as siderophore
components in Trojan Horse antimicrobials, which were
shown to penetrate at least the outer membrane of Gram-
negative bacteria, including E. coli.43,44
We anticipated compound 1 to possess similar iron-binding
properties to the tetradentate linear enterobactin dimer45
(Figure 2) and a previously described salmochelin S1 mimic,46
as both feature similar 2,3-dihydroxybenzamide iron-chelating
moieties attached to a 5-atomic backbone. We have previously
investigated the Fe3+ coordination chemistry of these two
tetradentate bis(catecholates) by using both UV−vis and CD
spectroscopy and observed rapidly equilibrating mixtures of
1:1 and 2:3 complexes, both monomers and dimers. In
compound 1, however, the deprotonated carboxylic acid and
adjacent carbonyl donor of the ciprofloxacin moiety could act
as an additional third iron chelating unit and hence affect the
iron-binding properties.47,48
The C5-β-glycosyl-2,3-dihydroxybenzoyl units of salmoche-
lin S4 (highlighted in Figure 2) were amalgamated into the
design but connected via Nα,Nε of L-lysine, with the C-
terminus providing an appropriate handle for attachment of
the parent antibiotic, ciprofloxacin. Suitably functionalized
catechol units were synthesized using previously described
methodologies. Commercially available methyl 3-methoxysali-
cylate 2 was iodinated with iodine monochloride49 and then
demethylated. This was followed by benzylation of the free
phenolic hydroxyl groups to give 3. Acetyl-protected β-glucose
was installed via nickel-promoted Negishi coupling using an
adapted literature procedure50,51 to give aryl-C-glucoside 4.
The glucosyl acetyl protecting groups of 4 were substituted
with benzyl ethers, resulting in the formation of two
compounds 5 and 6, which were combined and then
hydrolyzed to give the free carboxylic acid 7 (Scheme 1).50
In order to furnish a suitably functionalized antimicrobial to
allow the salmochelin analogue to be constructed, L-lysine-
appended ciprofloxacin 10 was synthesized as shown in
Scheme 2. Commercially available ciprofloxacin was converted
into its benzoyl ester 8 via a transient t-butyloxycarbonyl
nitrogen protection/deprotection strategy. It was then coupled
to Nα,Nε-diboc-L-lysine via EDC-mediated amide formation to
give 9.
Deprotection of the lysine-associated protecting groups
yielded 10. Lysine functionalized ciprofloxacin was coupled
with glucosylated catechol 7 to give benzyl-protected
salmochelin-inspired conjugate 11. Global debenzylation with
Pearlman’s catalyst52 furnished salmochelin-inspired ciproflox-
acin conjugate 1 in a moderate yield. Experimental details are
provided in the Supporting Information.
Fe3+ Complex Formation. The Fe3+ complex of 1 (1:1
ratio) was prepared by combining equimolar amounts of 1,
dissolved in DMSO, and FeCl3 hexahydrate, dissolved in water.
The solvents were removed in vacuo, and the resulting residue
was taken up in a volatile buffer (ammonium acetate) to enable
the species formed at pH 7.4 to be examined by native ion
mass spectrometry (experimental details are provided in the
Supporting Information). Complexation was confirmed by
UV−vis spectroscopy (Figure S1). The observed λmax of the
ligand-to-metal charge transfer band at 544 nm is consistent
with the prevalence of a chromophore in which two
catecholate units are coordinated to Fe3+, i.e., an equimolar
Fe3+-to-1 ratio.46
Interestingly, the negative ion ESI mass spectrum showed
evidence for the formation of both 1:1 and 2:2 species, the
latter consisting of two Fe3+ cations and two 15− ligands
(Scheme S1). The most abundant ions were observed at m/z
553.1336, 583.1437, 737.8462, and 1107.2695. On the basis of
their isotope patterns and charges, these peaks could be
assigned to the acetate adduct of the monomeric species
[Fe3+L5− + acetate− + H+]2−, and the dimeric species
[(Fe3+L5−)2]
4−, [(Fe3+L5−)2 + H
+]3− and [(Fe3+L5−)2 +
2H+]2− (Figure S2). The equilibrium shifts slowly from the
monomeric toward dimeric species over the course of several
days (Figure S2a−c).
The composition of these ions suggests that the acetate in
the 1:1 species and the carboxylate and keto O-donors of
ciprofloxacin in the 2:2 species may be recruited to complete
the 6-fold coordination sphere of the iron center. Due to the
rigid nature of ciprofloxacin, its O-donor atoms can only
coordinate to an adjacent iron center, and this may trigger
dimer formation. In addition, H-bonding interactions with the
glucose unit on the siderophore may support dimer formation.
In addition, a solution containing Fe3+ and conjugate 1 in a
2:3 ratio was prepared in an analogous way. The λmax of the
ligand-to-metal charge transfer band in the UV−vis spectrum
did not shift significantly (Figure S1), and the most abundant
ions observed in the negative ion ESI mass spectrum were
those assigned to 1:1 and 2:2 species, as above, plus free ligand
(conjugate 1). The formation of a 2:3 complex (Scheme S1)
was not apparent (Figure S3). This suggests that the
coordination of a third ligand is not favored in this case,
potentially due to steric hindrance or competitive binding of
the acetate or keto and/or carboxylate O-donors of the
ciprofloxacin unit.
Antibacterial Activity Testing. The antibacterial activity
of both 1 and the parent drug ciprofloxacin was tested against
Scheme 1a
a(i) AgNO3, ICl, pyridine, CHCl3, 68%; (ii) (1) BBr3, CH2Cl2, (2)
H2SO4, CH3OH, 91%; (iii) benzyl bromide, NaI, DMF, 72%; (iv) 1-
bromo-α-D-glucose tetraacetate, Zn, LiCl, Ni(COD)2,
tBuTerpy,
DMF, 63%; (v) (1) Na2CO3, MeOH, (2) benzyl bromide, NaH,
Bu4NI, DMF, 5 + 6 74%; (vi) NaOH, THF/MeOH (3:1), 87%.
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two bacterial strains: (1) E. coli K12 (BW25113), a common
laboratory strain that does not express IroN, the outer
membrane receptor protein required for active salmochelin
uptake,25 and (2) E. coli Nissle 1917, a probiotic strain that
expresses IroN and is able to utilize salmochelin.29 In addition
to serving as a negative control, the K12 strain was investigated
to confirm that nonpathogenic bacterial strains that are unable
to utilize salmochelin remain unaffected. The size of 1 renders
it unlikely to be taken up passively via porins, OmpF or
OmpC.53−57 OmpF is considered the main uptake pathway for
ciprofloxacin but has a molecular weight limit of around 600
Da.58 In the absence of active transport or porin-mediated
uptake, passive diffusion across the outer membrane is a
possibility; this has been suggested to occur for ciprofloxacin,
although to a much lesser degree than uptake via porins.59
However, it is unlikely that 1, with a projected polar surface
area of 401 Å,60 would display a similar capacity as
ciprofloxacin for passive diffusion, with a corresponding
approximated polar surface area of 82 Å, in its zwitterionic
form; a high polar surface area correlates strongly with
decreased membrane permeability.61
It was hoped that the presence of the salmochelin transport
machinery in Nissle 1917 would support active uptake of the
Fe3+ complex of 1 and hence increase its antibacterial activity,
thereby allowing the selective targeting of this strain.
The antibacterial activity assays were carried out in MOPS
acetate minimal media,62 either in the presence of 100 μM
Fe3+ (iron replete conditions) or with no added Fe3+ (iron
deplete conditions, <18 pM Fe). Details of the composition
and iron content of the media are provided in the Supporting
Information.
As expected, in E. coli K12 (BW25113), which lacks the
IroN transporter, 1 demonstrated a much lower antibacterial
activity than ciprofloxacin under both iron replete and iron
deplete conditions. Disappointingly, when the activity was
tested against Nissle 1917, capable of expressing IroN, a similar
lack of activity of 1 was observed, suggesting that active uptake
of 1 is not taking place (Table 1). This observation led to a
further investigation of factors limiting uptake/activity (vide
inf ra).
Antibacterial Activity vs E. coli K12 (BW25113).
Conjugate 1 was added to the growth media at varying
concentrations (0−100 μM, Figure 6). At higher concen-
trations of 1 in iron replete conditions, immediate Fe3+-
chelation was evident by the emergence of a characteristic
purple color due to Fe3+−siderophore complex formation.45
Due to the significant absorbance of these complexes at 600
nm, the optical density of the cell cultures is displayed at 800
nm (OD800). As expected, at plateaued bacterial growth (after
48 h) and in the absence of antimicrobial agents, the bacterial
cell density obtained in Fe3+ replete media was more than
twice as high as that obtained under Fe3+ limitation (Figures 6
and S6).
In iron replete media, ciprofloxacin, the parent antimicrobial
of 1, was active at low concentrations between 0.1 and 1 μM
(Figure 7a), while 1 only showed growth suppression once the
concentration started to approach that of Fe3+ in the growth
medium (>75 μM). In iron deplete conditions, a clear growth
Scheme 2a
a(i) (1) Boc2O, NaOH, 1,4-dioxane, H2O, (2) benzyl bromide, Cs2CO3, DMF, (3) TFA, CH2Cl2, 51%; (ii) Nα,Nε-Boc-lysine, EDC·HCl, HOBt·
H2O, DIPEA, DMF, 55%; (iii) TFA, CH2Cl2, 100%; (iv) 7, EDC·HCl, HOBt·H2O, DIPEA, DMF, 42%; (v) Pd(OH)2/C, H2, MeOH/EtOAc
(1:1), 45%.
Table 1. MIC Values of Conjugate 1 and Ciprofloxacin
(cipro) Determined in Acetate/MOPS Minimal Media
under Iron Replete (100 μM Fe3+) and Deplete (<18 pM
Fe) Conditions









1 >100 75 >100 100
cipro 1 1 0.1 8
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inhibitory effect was already observed at a 25 μM
concentration of 1. While the latter might be an indication
of salmochelin-mediated uptake of 1, the attenuation of
bacterial growth may also be attributed to the competition of 1
with native siderophores for the more limited Fe3+ resource,
starving the cells of the vital nutrient. Again, the antibacterial
activity of 1 was much lower than that of the parent antibiotic
ciprofloxacin (∼75×, Figure 7b). Hence, to further explore the
relationship between siderophore-mediated Fe3+ uptake and
the antibacterial activity of 1, a radiolabeling study with the
Fe3+-mimetic 67Ga3+ was undertaken.
67Ga-Radiolabeling and Bacterial Uptake. Hexadentate
siderophores exhibit exceptionally high affinity for both Fe3+
and the nonredox active, Fe3+-mimetic Ga3+ (KD > 10
−30 M).63
Functionalized Ga3+ and Fe3+ siderophore complexes are both
efficiently recognized by bacterial siderophore membrane
transporters, indicating that bacteria cannot distinguish the
trivalent ions at the time of siderophore-mediated entry. Ga3+
represents an ideal surrogate to study the behavior of Fe3+
complex species.64,65 Commercial availability of two radio-
active imaging isotopes of Ga3+, 68Ga (t1/2 = 1.1 h), a positron
emission tomography (PET) imaging isotope, and 67Ga (t1/2 =
3.3 d), a longer lived isotope utilized for single photon
emission computed tomography (SPECT), provides oppor-
tunities to study the stability and pharmacokinetics of Ga−
siderophore complexes in vitro and in vivo. Indeed, this
approach has already been explored for the imaging of fungal
infections in rats, taking advantage of the siderophore-
mediated uptake of 68Ga in fungi such as A. fumigatus,66 as
well as the assessment of a novel desferrichrome-based
conjugate that exhibited enhanced potency in Gram-positive
and Gram-negative strains.19
Here, we elected to use 67Ga, as the longer half-life of this
isotope permits extensive long-term stability and internal-
ization studies. It has been shown that 67Ga-labeled deferox-
amine (DFO) retains active uptake via bacterial Fe3+-transport
in S. aureus with DFO acting as a xenosiderophore.67,68 In
order to synthesize 67Ga-1, we first transformed 67Ga-citrate to
GaCl3 and monitored the radiolabeling of 1 by radio-HPLC.
19
Complexation proceeds quickly with quantitative yield,
producing an apparent molar activity of 90 nmol/MBq. In
order to probe if the 67Ga-1 was sufficiently inert for
subsequent uptake experiments, we monitored complex
inertness in LB broth over the course of 2 h, during which
no significant dechelation was observed. Next, we assessed the
time-dependent bacterial uptake of 67Ga-1 in E. coli K12
(MG1655) in iron replete LB over 2 h. The percentage of
internalized 67Ga-1 was <10% of the total 67Ga and comparable
to the uptake of a 67Ga-citrate control. The results in iron
deplete LB media were similar, with <10% internalization,
comparable to that seen with 67Ga-citrate (Figure 8).
To confirm if this measured uptake mirrored low transport
into bacteria, with the resultant absence of activity, the study
was expanded to assess three compounds previously reported
by us, staphyloferrin A-inspired conjugates 12, 13, and 14
(Figure 9).40 These conjugates retain and mirror the original
siderophore structure more closely and provide a 6-coordinate
ligand environment for corresponding Fe3+ and Ga3+
complexes. These compounds showed activity against E. coli
NCTC10418 and some inhibition of DNA gyrase in vitro,
albeit at a lower level than the parent ciprofloxacin.41 All three
compounds have an estimated polar surface area of 329 Å
when fully protonated. In analogy to 67Ga-1, 67Ga-12, 67Ga-13,
and 67Ga-14 were synthesized under identical conditions.
Figure 6. E. coli K12 (BW25113) growth in minimal media (MOPS
acetate) in the presence of 1 at t = 48 h in (a) iron replete (striped
bars) and (b) iron deplete (solid bars) conditions.
Figure 7. E. coli K12 (BW25113) growth in minimal media (MOPS
acetate) in the presence of ciprofloxacin at t = 48 h in (a) iron replete
(striped bars) and (b) iron deplete (solid bars) conditions.
Figure 8. Time-dependent, radiochemical bacterial uptake studies in
E. coli K12 (MG1655) of 67Ga-1 in iron replete (striped bars) and
iron deplete (solid bars) media. Error bars calculated as standard
deviation of n = 5.
Figure 9. Structures of staphyloferrin A−ciprofloxacin conjugates
12−14.
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The radiolabeled complexes were less stable than 67Ga-1 in
both iron replete and iron deplete LB broth, exhibiting the
percentage of intact radiochemical complexes ranging from
67Ga-14 (70%) to 67Ga-12 (60%) and 67Ga-13 (50%). No
further trans-chelation was observed after 9 h, indicating that a
relative equilibrium state is reached. In iron deplete LB broth,
complex stability was marginally lower but again was
maintained over 9 h.
To assess relative complex inertness in comparison with the
6-coordinate chelator ethylenediamine-tetraacetate (EDTA),
the radiochemical gallium complexes were challenged with a
10-fold excess with respect to conjugate concentration.
Complex inertness was monitored using radio-HPLC. After 2
h, the relative inertness can be ranked as follows: 67Ga-14 >
67Ga-12 > 67Ga-13 > 67Ga-1 (Figure S11). This result indicates
that, in the presence of a six-coordinate, competing chelator,
the trans-chelation from a 4-coordinate donor such as 1 occurs
rapidly; the 6-coordinate, staphyloferrin-based conjugates
provide a more inert coordination environment, with the
lysine-derived structure, 67Ga-14, showing the best stability in
this challenge assay.
Uptake experiments in E. coli K12 (MG1655) in both iron
replete and deplete LB broth were assessed in comparison with
67Ga-1. Although still low (up to 14.7% after 0.33 h for 67Ga-
13, Figure 10), the uptake of all three conjugates was higher
than that observed with the 67Ga-citrate control and marginally
higher than that observed with 67Ga-1, suggesting a very
modest degree of translocation through bacterial cell
membranes, corroborating antibacterial activity results ob-
tained in previous work.40−42
Antibacterial Activity vs E. coli Nissle 1917. The
antibacterial activities of 1 and ciprofloxacin were also assessed
against a strain of E. coli capable of producing and transporting
salmochelin, E. coli Nissle 1917. The probiotic Nissle 1917
shares many characteristics with uropathogenic E. coli strains,
including the ability to produce several siderophores,
specifically salmochelin, enterobactin, yersiniabactin, and
aerobactin, to be able to adapt to environmental challenges.29
It was hoped that the presence of the salmochelin transport
machinery, including the outer membrane transporter IroN,25
would increase the bacterial uptake and hence antibacterial
activity of 1 in Nissle 1917.
However, the antimicrobial activity of 1 was found to be
similar to that observed with the K12 strain. In iron replete
media, clear growth inhibition was only seen at 100 μM
concentrations and above, when the concentration of 1
reached the 100 μM concentration of Fe3+ (Figure 11a).
This suggests that, under these conditions, the sequestration of
Fe3+ by the siderophore unit of 1 becomes so significant that it
deprives the growth medium of this vital nutrient. The fact that
ciprofloxacin already suppresses growth at ∼1000× lower
concentrations (0.1 μM, Figure 12a) is consistent with a lack
of bacterial uptake of 1.
In iron deplete media, a slight growth inhibitory effect is
already evident at a 1 μM concentration of 1 (Figure 11b).
This observation is consistent with both a fiercer competition
between the siderophore unit of 1 and native siderophores for
the small amount of Fe3+ available in the deplete medium and
the siderophore-mediated uptake of 1. However, if active
uptake is occurring, the lower activity of 1 compared to that of
ciprofloxacin (Figure 12b) suggests that it is insufficient to
compensate for the decrease in uptake of the antimicrobial via
porins and passive diffusion caused by attachment of the
salmochelin unit in 1, even though the expression of high-
affinity siderophore transport proteins, such as IroN, should be
upregulated under Fe3+ limited conditions.69 The observation
that the activity of 1 vs E. coli Nissle 1917 is significantly lower
than that of its parent drug ciprofloxacin led us to consider
poor binding to the drug target DNA gyrase as an additional
possible reason for the observed reduction in potency.
Gyrase Inhibition Assay. A key factor in the antimicrobial
activity of ciprofloxacin conjugates is their continued ability to
inhibit DNA gyrase, the cytoplasmic drug target of
ciprofloxacin. In order to investigate the impact of
Figure 10. Time-dependent, radiochemical bacterial uptake studies in
E. coli K12 (MG1655) of 67Ga-staphyloferrin conjugates 12−14 in
iron replete (striped bars) and iron deplete (solid bars) media. Error
bars calculated as standard deviation of n = 5.
Figure 11. E. coli Nissle 1917 growth in minimal media (MOPS
Acetate) in the presence of 1 at t = 48 h in (a) iron replete (striped
bars) and (b) iron deplete (solid bars) conditions.
Figure 12. E. coli Nissle 1917 growth in minimal media (MOPS
acetate) in the presence of ciprofloxacin at t = 48 h in (a) iron replete
(striped bars) and (b) iron deplete (filled bars) conditions.
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salmochelin-inspired siderophore conjugation on the ability of
ciprofloxacin to inhibit gyrase, 1 was evaluated in an in vitro
assay using a commercial DNA gyrase supercoiling assay.
Initially, 1 was studied over a range of concentrations (0.5−20
μM) and no inhibition of gyrase activity was observed, as
indicated by no reduction in the presence of supercoiled DNA
plasmids on agarose gels (Figure 13). Inhibition of the
intracellular drug target DNA gyrase by 1 was detectable at
concentrations of 30 μM and above, with complete inhibition
at 75 μM (Figure 14), indicating a decrease in gyrase
inhibitory activity in comparison with the parent drug (10
μM). However, this moderate decrease in gyrase inhibitory
activity does not explain the drastic drop in the antibacterial
potency of 1.
This, plus the lack of higher activity vs the Nissle 1917
strain, suggests that poor active transport of 1 is a major factor
in the observed lack of antimicrobial activity against both
strains of E. coli.
■ SUMMARY AND CONCLUSIONS
A ciprofloxacin siderophore conjugate 1 has been synthesized
by linking glycosylated catechol units 7, found in salmochelin
S4, to L-lysine modified ciprofloxacin 10. The resulting
siderophore−ciprofloxacin conjugate was designed to evade
the mammalian immune response and to selectively target
pathogenic bacteria that express the salmochelin receptor IroN.
Initial screening of 1 against a common laboratory strain of
E. coli lacking the IroN transporter demonstrated much
reduced antibacterial activity compared to the parent antibiotic
ciprofloxacin, with concentrations ca. 250−1000× higher than
required to obtain similar activity in identical conditions.
Increased antibacterial activity was observed in iron deplete
media. Probing cellular uptake via 67Ga labeling suggested the
absence of significant bacterial cell uptake of 67Ga-1, consistent
with the absence of IroN.
When the activity was examined vs Nissle 1917, a strain
capable of expressing IroN, a similar concentration depend-
ence was observed, with 1 again requiring concentrations 250−
1000× higher than ciprofloxacin to obtain similar growth
inhibition, suggesting the presence of IroN did not lead to
significantly greater uptake. Again, higher activity was observed
in iron deplete media.
While the DNA gyrase inhibitory activity of 1 was
significantly lower than that of the parent drug, the relatively
moderate decrease in gyrase inhibitory activity does not
explain the drastic drop in the antibacterial potency of 1.
These results suggest that one major obstacle in the
successful application of salmochelin-based Trojan Horse
antibiotics with an intracellular drug target is the delivery of
the conjugate into the bacterial cell via Fe3+-siderophore
transporters.
The observed formation of dimeric 2:2 species by native
mass spectrometry provides a potential explanation for the
observed lack of cellular uptake of conjugate 1. If the tendency
to form dimers also applies to biological media, it is unlikely
that these dimers would be recognized by the outer membrane
receptor IroN and fit through the iron−salmochelin trans-
porter.
Hence, our first generation conjugate, 1, the tetradentate
mimic of the hexadentate siderophore salmochelin S4, appears
poorly suited to target the salmochelin-mediated uptake
pathway. A similar relationship was observed for enter-
obactin−ciprofloxacin Trojan Horse conjugates by Nolan
and co-workers,18 who observed that an intact hexadentate
enterobactin unit was required for good antibacterial activity,
whereas tetradentate or bidentate equivalents displayed poor
activity, possibly due to reduced recognition by the
corresponding outer membrane receptor.18 It is also
conceivable that the lack of a flexible linker between the
siderophore component and ciprofloxacin renders 1 too rigid
and bulky to be able to pass through the IroN transporter or
the closely linked ciprofloxacin directly impedes siderophore
binding.
The poor cellular uptake shown in the case of 1, along with
its increase in activity in iron deplete media, may point to
extracellular Fe3+ sequestration as an additional mechanism of
action, alongside DNA gyrase inhibition.
While the lack of significant uptake and activity of 1 is
disappointing, it offers some direction to a future second
generation design. The size and polar surface area of the
conjugate are sufficient to prevent passive uptake via porin
channels or passive diffusion through the cell membrane,
suggesting that optimization of the siderophore component
and linker to boost uptake in salmochelin-utilizing strains
could be sufficient to transform similar conjugates into narrow-
spectrum antimicrobials. In addition, while the application of a
biolabile linker designed to cleave the ciprofloxacin from the
siderophore inside the cell could retrieve the DNA inhibitory
activity, a biolabile link will not increase antibiotic efficacy
unless the conjugate is delivered, at an appropriate level, into
the bacterial cytoplasm. Future studies will be focused on
optimizing active conjugate transport into bacterial cells using
a combination of targeted chemical synthesis and radiolabeled
67Ga complex uptake studies.
Figure 13. DNA gyrase assay of (A) ciprofloxacin and (B) conjugate
1. 0 μM = DMSO control. + = positive control, with DNA gyrase
present without the antimicrobial. − = negative control, no DNA
gyrase or antimicrobial.
Figure 14. DNA gyrase assay of conjugate 1 at concentrations ranging
from 100 to 20 μM.
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